AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
La batalla entre científicos por el fármaco del alzhéimer: ¿cura prometedora o riesgo inaceptable?
Hoy en EL PAÍS
Intereses comerciales en la investigación sobre el alzhéimer
Este capítulo explora el debate sobre los fármacos para el alzhéimer, centrándose en el Ecanemab y el controvertido Aducanumab. Se examinan los intereses comerciales y los conflictos de interés que rodean la aprobación de estos tratamientos, así como las presiones que enfrenta la industria farmacéutica.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode